Search by Drug Name or NDC
NDC 70710-1350-03 Venlafaxine 150 mg/1 Details
Venlafaxine 150 mg/1
Venlafaxine is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Zydus Pharmaceuticals USA Inc.. The primary component is VENLAFAXINE HYDROCHLORIDE.
MedlinePlus Drug Summary
Venlafaxine is used to treat depression. Venlafaxine extended-release (long-acting) capsules are also used to treat generalized anxiety disorder (GAD; excessive worrying that is difficult to control), social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life), and panic disorder (sudden, unexpected attacks of extreme fear and worry about these attacks). Venlafaxine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SNRIs). It works by increasing the amounts of serotonin and norepinephrine, natural substances in the brain that help maintain mental balance.
Related Packages: 70710-1350-03Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Venlafaxine
Product Information
| NDC | 70710-1350 |
|---|---|
| Product ID | 70710-1350_479c565e-3c2f-42a1-8a19-b7a210e5f28d |
| Associated GPIs | |
| GCN Sequence Number | 064446 |
| GCN Sequence Number Description | venlafaxine HCl TAB ER 24 150 MG ORAL |
| HIC3 | H7C |
| HIC3 Description | SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS) |
| GCN | 14353 |
| HICL Sequence Number | 008847 |
| HICL Sequence Number Description | VENLAFAXINE HCL |
| Brand/Generic | Generic |
| Proprietary Name | Venlafaxine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Venlafaxine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/1 |
| Substance Name | VENLAFAXINE HYDROCHLORIDE |
| Labeler Name | Zydus Pharmaceuticals USA Inc. |
| Pharmaceutical Class | Norepinephrine Uptake Inhibitors [MoA], Serotonin Uptake Inhibitors [MoA], Serotonin and Norepinephrine Reuptake Inhibitor [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA215622 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 70710-1350-03 (70710135003)
| NDC Package Code | 70710-1350-3 |
|---|---|
| Billing NDC | 70710135003 |
| Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (70710-1350-3) |
| Marketing Start Date | 2022-09-01 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.22178 |
| Pricing Unit | EA |
| Effective Date | 2023-09-20 |
| NDC Description | VENLAFAXINE HCL ER 150 MG TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |